Drug Trial Radar · NCT01510028
Multicenter Study of HGT-1110 Administered Intrathecally in Children With Metachromatic Leukodystrophy (MLD)
Last checked: Nov 20, 2026Latest source record: Jun 14, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Feb 2, 2012
Primary completion
Jan 20, 2017
Study completion Jan 20, 2017
Sponsor
- Lead sponsor
- ShireTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Jan 13, 2012
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, up to 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the safety of ascending doses of HGT-1110 administered by intrathecal (IT) injection for 38 weeks (20 injections) in children with metachromatic leukodystrophy (MLD).
Conditions
- Metachromatic Leukodystrophy (MLD)
Interventions
Recombinant human arylsulfatase ABiological
6 patients treated with HGT-1110 EOW by IT injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment Emergent Adverse Events (TEAEs) by Type and SeverityTime frame: From start of study treatment up to Week 42
- Number of Participants With Clinical Laboratory Abnormalities Reported as Treatment Emergent Adverse Events (TEAEs)Time frame: From start of study treatment up to Week 40
- Number of Participants With Vital Sign Abnormalities Reported as Treatment Emergent Adverse Events (TEAEs)Time frame: From start of study treatment up to Week 40
- Number of Participants With Electrocardiogram (ECG) Abnormalities Reported as Treatment Emergent Adverse Events (TEAEs)Time frame: From start of study treatment up to Week 40
- Number of Participants With Clinically Significant Abnormalities in Physical Examination Reported as Treatment Emergent Adverse Events (TEAE)Time frame: From start of study treatment up to Week 40
- Number of Participants With Cerebrospinal Fluid (CSF) Chemistry Abnormalities Reported as Treatment Emergent Adverse Events (TEAEs)Time frame: From start of study treatment up to Week 40
- Number of Participants With Positive Anti-SHP611 Antibodies in Cerebrospinal Fluid (CSF) and or SerumTime frame: Baseline up to Week 40
Locations
5 sites in 5 countries. Site status is shown where the registry gives one.
The Children's Hospital at Westmead
Westmead, Australia
Rigshospitalet
Copenhagen, Denmark
Hopital de Bicetre
Le Kremlin-Bicêtre, Île-de-France Region, France
Center for Pediatric Clinical Studies
Tübingen, Baden-Wurttemberg, Germany
Osaka University Hospital
Suita, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.